Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Patent
1972-05-05
1976-01-13
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
A61K 1706
Patent
active
039326357
ABSTRACT:
This invention relates to a method of fertility control by use of novel cyclic progestogen-interrupted estrogen oral contraceptive regimens. Considering the first day of menstrual flow as day one of a 28 day medication administration cycle, a combined formulation of estrogen and progestogen substances is administered on the 3rd, 4th, 5th or 6th day of the cycle and every second or third day thereafter through, and including, the 23rd, 24th, 25th, 26th, 27th or 28th day of the cycle, and a formulation having only a progestogen substance as the active component is administered on the 4th, 5th, 6th, or 7th day of the cycle and every day thereafter on which a combination formulation is not administered, through, and including, the 22nd, 23rd, 24th, 25th, 26th, 27th or 28th day of the cycle.
In a particular regimen, a combination of estrogen and progestogen is administered starting with the 5th day of the cycle and continuing every other day through the 25th day of the cycle, and starting with the 6th day of the cycle and continuing every other day through the 24th day of the cycle only progestogen is administered. The remaining seven days are dosage-free or the regimen is completed by use of placebos or other nonhormonal supplements.
Dispensing packages for holding unit dosage forms for oral ingestion of one unit dosage form daily in the appropriate sequence during a single cycle of medication administration are also described.
REFERENCES:
patent: 3409721 (1968-11-01), Applezweig
patent: 3591688 (1971-07-01), Jones et al.
patent: 3624203 (1971-11-01), Overbeek
patent: 3660574 (1972-05-01), Berman
patent: 3755573 (1973-08-01), Berman
Haspels, A. A., Fortschritte Der Therapie 90(Suppl.):595-600, May 18, 1972, "Die Pille Danach"- "Experience of 1,000 Women with the Postcoital Administration of High Estrogen Doses".
Haspels, A. A., I.P.P.F. Medical Bull. 3:6-(1969), "The Morning After Pill-A Preliminary Report".
Morris, et al., Amer. J. Obstet. Gynec., 96:804-815, Nov. 15, 1966 "Compounds Interfering with Ovum Implantation and Development III the Role of Estrogens".
Ball, Canad. Med. Assn. JL.105: 240, Aug. 7, 1971, "The Morning-After Pill".
Rudel, Fed. Proc. 29:1228-1231, May, June 1971, Antifatility Effects of Low Dose Progestin.
Cox, J. Reprod. Fert. Suppl. 5, (1968:167-172, The pre-coital use of Mini-Dosage Progestogens.
Foss, J. Reprod. Fert. Suppl., 5(1968):145-154, Oral Contraception with Continuous Microdosage of Norgestrel.
Rudel et al., IBPT, Sect, 48 Vol. 385-417, (1972), "Oral Contraceptives, Hamon Fertility Studies and Side Effects," Pergamon Press, N.Y. (1972).
Green Blatt Fertility & Sterility 18:207-211, (1967), One Pill a Month Contraceptive.
Coutinho et al., J. Reprod. Fert. 16:137-139, (1968), The Every Other Day Pill.
Lotvin et al., Obstet. Gynocol. 35:933-936, June 1970, Once A Month Oral Contraceptive Quinestrol and Quingestanol.
Claman, Amer. J. Obstet. Gynec.107:461-464, June 1970, A Trial of a One Dose a Month Oral Contraceptive.
Hirsch Joseph I.
Rose Shep K.
Syntex Corporation
Walker William B.
LandOfFree
Novel cyclic progestogen-interrupted estrogen oral contraceptive does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel cyclic progestogen-interrupted estrogen oral contraceptive, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel cyclic progestogen-interrupted estrogen oral contraceptive will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-748040